Ensign Peak Advisors
EBS icon

Ensign Peak Advisors’s Emergent Biosolutions EBS Stock Holding History

Ensign Peak Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,766
Closed -$352K – 1912
2022
Q3 		$352K Sell
16,766
-1,110
-6% -$30.9K ﹤0.01% 1634
2022
Q2 		$555K Hold
17,876
– – ﹤0.01% 1417
2022
Q1 		$734K Hold
17,876
– – ﹤0.01% 1373
2021
Q4 		$777K Sell
17,876
-19,960
-53% -$903K ﹤0.01% 1408
2021
Q3 		$1.89M Hold
37,836
– – ﹤0.01% 1161
2021
Q2 		$2.38M Sell
37,836
-11,896
-24% -$764K ﹤0.01% 1020
2021
Q1 		$4.62M Sell
49,732
-6,057
-11% -$620K 0.01% 655
2020
Q4 		$5M Buy
55,789
+2,031
+4% +$186K 0.01% 607
2020
Q3 		$5.55M Buy
53,758
+15,922
+42% +$1.72M 0.01% 593
2020
Q2 		$2.99M Hold
37,836
– – 0.01% 776
2020
Q1 		$2.19M Buy
37,836
+2,800
+8% +$161K 0.01% 792
2019
Q4 		$1.89M Buy
+35,036
New +$1.9M 0.01% 1092

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ensign Peak Advisors's EBS Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Emergent Biosolutions (EBS) in Q4 2022, closing a stake of 16,766 shares — an estimated $352K sold.

Ensign Peak Advisors first reported a position in EBS in Q4 2019 and held it in 12 quarters. The position peaked at $5.55M in Q3 2020. 198 funds tracked by Wall St. Rank hold EBS as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Emergent Biosolutions position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 16,766 Emergent Biosolutions shares in Q4 2022, an estimated $352K.
  • Ensign Peak Advisors first reported a position in Emergent Biosolutions in Q4 2019 and held it in 12 quarters.
  • Ensign Peak Advisors's Emergent Biosolutions position peaked at $5.55M in Q3 2020.
  • 198 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.